Gosoka Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 18 Year, 11 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -1.04%
- Profit Growth 96.17%
- Ebitda 241.05%
- Net Worth -1.06%
- Total Assets -3.34%
About Gosoka Pharmaceuticals
Gosoka Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 February 2007 and has a history of 18 years. Its registered office is in Mahesana, Gujarat, India.
The Corporate was formerly known as Gskp Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Govindbhai Patel, Bhavik Shah, Somabhai Patel, and Two other members serve as directors at the Company.
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24232GJ2007PTC050029
- Company No.
050029
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Gosoka Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govindbhai Patel  | Director | 15-Feb-2007 | Current |
| Bhavik Shah | Director | 15-Feb-2007 | Current |
| Somabhai Patel | Director | 15-Feb-2007 | Current |
| Kaminiben Patel | Director | 15-Feb-2007 | Current |
| Nehaben Shah | Director | 15-Feb-2007 | Current |
Financial Performance of Gosoka Pharmaceuticals.
Gosoka Pharmaceuticals Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 1.04% decrease. The company also saw a substantial improvement in profitability, with a 96.17% increase in profit. The company's net worth dipped by a decrease of 1.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gosoka Pharmaceuticals?
In 2019, Gosoka Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gosoka Pharmaceuticals?
Unlock and access historical data on people associated with Gosoka Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gosoka Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gosoka Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
